A Phase 3b, Open-label, Multicenter, Continued Access Study for Participants Transitioning From ViiV Healthcare Sponsored or ViiV Healthcare Collaborative Parent Studies for HIV Treatment

The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.

开始日期2026-05-08

申办/合作机构

ViiV Healthcare Ltd.

NCT07030920

/ Recruiting临床2期IIT

Reducing Systemic Inflammation in People on Antiretroviral Therapy

This randomized, open-label clinical trial will evaluate whether adding fostemsavir to current antiretroviral therapy can reduce the risk of cardiovascular disease in people with well-controlled HIV. Researchers will compare imaging, clinical and biomarker outcomes between participants who receive fostemsavir in addition to their existing treatment and those who continue with standard care alone.

开始日期2025-09-30

申办/合作机构

McGill University Health Centre

[+1]

NCT07053384

/ Active, not recruiting临床1期

An Exploratory Phase 1b, Multicenter, Randomized, Open-Label Study to Investigate the Impact of the Administration of Intravenous VH3810109 With or Without Oral Fostemsavir in Combination With Integrase Inhibitor-Based Antiretroviral Therapy on the Viral Reservoir in Adults Living With HIV-1

This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2).

开始日期2025-07-10

申办/合作机构

ViiV Healthcare Ltd.

100 项与磷坦姆沙韦相关的临床结果

登录后查看更多信息

100 项与磷坦姆沙韦相关的转化医学

登录后查看更多信息

100 项与磷坦姆沙韦相关的专利（医药）

登录后查看更多信息

159

项与磷坦姆沙韦相关的文献（医药）

2026-03-01·HIV MEDICINE

Exploring the impact of baseline and on‐treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study

Article

作者: Krystal, M. ; Du, F. ; Wang, X. ; Pierce, A. ; Li, B. ; Gartland, M. ; Tenorio, A. R. ; Castillo‐Mancilla, J. R. ; Liao, Q.

Abstract:

Objectives:

The gp120‐directed attachment inhibitor fostemsavir was effective in people with multidrug‐resistant (MDR) HIV‐1 in the BRIGHTE study. Understanding factors associated with virologic response can help clinicians optimize treatment and identify individuals for fostemsavir‐based regimens. In previous multivariable analyses, baseline CD4+ T‐cell count, baseline log 10 HIV‐1 RNA and temsavir plasma concentration were associated with virologic response through 24 weeks. This expanded analysis evaluated predictors of the durability of response at Weeks 96 and 192.

Methods:

BRIGHTE participant data (Randomized Cohort [RC], n = 272; Non‐randomized Cohort, n = 99) were evaluated to examine baseline factors associated with virologic outcomes (HIV‐1 RNA <40 copies/mL [Snapshot]; protocol‐defined virologic failure [PDVF]) using linear/logistic regression with stepwise selection. A separate analysis evaluated baseline factors for association with treatment‐adherent PDVF.

Results:

In RC participants, higher baseline log 10 HIV‐1 RNA, lower number of fully active available antiretrovirals in initial optimized background therapy (OBT) and a lower overall susceptibility score to newly used antiretrovirals in initial OBT were associated with lower odds of virologic response at Week 96. Baseline gp120 substitutions and dolutegravir use were additional factors through Week 192. Other baseline factors, including CD4+ T‐cell count <20 cells/mm 3 , HIV‐1 RNA ≥100 000 copies/mL, antiretroviral therapy duration >20 years or gp120 substitutions, had low predictive value for treatment‐adherent PDVF in RC participants (Week 96, 35%; Week 192, 39%).

Conclusions:

Multivariable analysis (MVA) identified several factors predictive of virologic response. No baseline factors were highly predictive of virologic failure at Weeks 96 or 192. Findings support the use of fostemsavir in diverse populations with MDR HIV‐1.

2026-02-18·JOURNAL OF INFECTIOUS DISEASES

Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV

Article

作者: Tolbert, William D ; Castagna, Antonella ; Clark, Andrew ; Finzi, Andrés ; Durand, Madeleine ; Prakash, Manyu ; Clemente, Tommaso ; Richard, Jonathan ; Benlarbi, Mehdi ; Chandravanshi, Monika ; Bourassa, Catherine ; Pazgier, Marzena

Abstract:

Background:

Heavily treatment-experienced (HTE) people with HIV (PWH) have limited antiretroviral therapy (ART) treatment options, putting them at greater risk of unfavorable human immunodeficiency virus 1 (HIV-1) disease progression. Fostemsavir (BMS-663068) efficiently suppressed viremia and increased CD4 count when combined with other antiretrovirals in HTE PWH. Its active metabolite, temsavir (BMS-626529, GSK2616713), binds a conserved pocket within the envelope glycoprotein (Env) CD4 binding site and prevents CD4-induced conformational changes. Temsavir effect on Env conformation profoundly alters its glycosylation and cleavage, thereby modifying its antigenicity and reducing gp120 shedding. Here we evaluated if fostemsavir treatment in PWH modulated the levels of nonneutralizing gp120 CD4-induced (CD4i) antibodies (Abs) associated with CD4 depletion in vitro and in PWH.

Methods:

We measured the levels of anti-gp120 CD4i Abs in plasma samples taken before and after fostemsavir treatment in HTE participants from the BRIGHTE trial and the PRESTIGIO registry and compared them to those of a control ART-treated group from the SAILING trial.

Results:

We observed a significant decline of anti-gp120 CD4i Abs in the 2 fostemsavir-treated HTE groups, but not in the control group. Moreover, this effect was unique to anti-gp120 CD4i Abs, as no significant changes were observed in the levels of antibodies targeting Gag. Functionally, this decline in CD4i Abs was associated with a reduced capacity of plasma to recognize and eliminate uninfected primary CD4+ T cells coated with soluble gp120.

Conclusions:

Altogether, fostemsavir may provide additional immune benefits to PWH, beyond blocking viral entry, by reducing anti-gp120 CD4i Abs levels.

Clinical Trials Registration:

NCT04098315, NCT01231516, and NCT02362503.

2026-02-18·JOURNAL OF INFECTIOUS DISEASES

“Fostemsavir: More Than Meets the Eye”

Communications

作者: Kogilwaimath, Siddharth ; Utay, Netanya S

项与磷坦姆沙韦相关的新闻（医药）

2026-03-23

·百奥赛图

最新嘉宾阵容｜百奥赛图BioX创新论坛 · 国际版：下一个十年的抗体疗法

会议背景在下一个十年的抗体疗法浪潮中，科学突破与跨国协作正成为驱动行业前行的核心引擎。如何从早期分子精准跨越至临床阶段？AI与创新平台如何进一步释放抗体多样性的潜力？跨国BD合作又将如何重塑全球医药资本与产业格局？ 2026年百奥赛图BioX创新论坛将于3月27日在上海盛大开启。本次论坛将汇聚来自全球生物医药企业、创新机构与投资领域的资深专家与行业同仁，共同交流前沿洞见，分享实践经验。论坛将聚焦T Cell Engagers (TCE)、mRNA递送、ADC等前沿赛道，围绕创新技术、产业协同与全球化发展趋势展开深入探讨，共同展望生物医药新纪元下的科学逻辑与商业未来。本次论坛采用报名审核制，席位有限，诚邀感兴趣的行业同仁一起交流！会议信息会议时间 2026年3月27日（周五）8:00-20:00 会议地点上海浦东（详细地址将在确认邮件中通知）会议规模上限100人，报名审核制会议最终解释权归百奥赛图所有会议日程 3月27日 08:00-08:50 会议签到 08:50-09:00 欢迎致辞沈月雷博士-百奥赛图，董事长兼CEO 09:00-09:30 Keynote 1: Development of Novel, CD8-guided, T Cell Engagers for the Treatment of Solid Tumors and Hematological Malignancies Saso Cemerski, Ph.D., AstraZeneca, Executive Director, Head of Immune Engagers 09:30-10:00 Keynote 2: Intranasal Delivery of mRNA for Immunity, Inflammation, and Neurodegeneration Bruce Turner, M.D., Ph.D., Xanadu Bio, Founder, CEO & Chairman 10:00-10:30 Keynote 3: Synthetic Interferons Demonstrate Potent Antiviral and Anti-Tumor Activity with the Potential for an Improved Safety Profile Wade Blair, Ph.D., IntegerBio, CSO 10:30-11:00 Keynote 4: From Capital to Collaboration: Investment and Company Building with China Yi Ding, Ph.D., RA Capital, BD Director 11:00-12:00 Panel 1: The Next Frontier of Innovative Therapeutics: From Early-Stage Molecules to Clinical Trials Benny Yang, Ph.D. (Moderator), Biocytogen, CSO Saso Cemerski, Ph.D., Bruce Turner, M.D., Ph.D., Wade Blair, Ph.D., Yi Ding, Ph.D. 12:00-13:00 午餐 13:00-13:30 Keynote 5: RenSuper Workstation: An AI-Driven Antibody Discovery Platform From Target to Antibody Leads in Clicks 沈月雷博士-百奥赛图，董事长兼CEO 13:30-14:00 Keynote 6: Discovery of Novel ADC DB-1317 and Novel DUP9 Payload 花海清博士-映恩生物，高级副总裁、药物发现负责人 14:00-14:30 Keynote 7: Translating Immunobiology to Medicine 刘勇军博士-小路生物&拓胜医药，创始人&董事长 14:30-15:00 Keynote 8: Accelerating Translation with Integrated Humanized Mouse Models and Pharmacology Platforms 刘瑜洁博士-百奥赛图，药理药效部总监 15:00-15:20 茶歇 15:20-16:20 Panel 1: 谁定义创新药的未来？-- MNC视角 Icy Niu（主持人），百奥赛图， Executive Director, Business & Global Marketing 祁昱博士，默沙东（MSD），全球业务拓展与授权总监方明博士，葛兰素史克（GSK），业务拓展高级总监李哲丰博士，礼来制药（Lilly），外部创新合作总监徐琳鑫雨博士，罗氏（Roche），对外合作部肿瘤领域搜寻与评估负责人沈蓉博士，辉瑞投资有限公司（Pfizer Investment），炎症与免疫领域搜寻与评估及中国本土项目负责人 16:20-17:20 Panel 2: 谁定义创新药的未来？-- 中国Biotech视角沈月雷博士（主持人），百奥赛图，董事长兼CEO 刘勇军博士，小路生物&拓胜医药，创始人&董事长江山博士，翰森制药集团有限公司，首席技术官王卓智博士，安博宁生命科技公司，首席科学官赵昊先生，君合律师事务所，合伙人 17:20-20:00 晚宴 & 酒会报名方式 ● 请扫描下方二维码填写报名表单，审核通过后，我们将在会前一周内发送确认邮件，并提供详细会议信息。期待您的加入，共谋行业创新发展，与变革者同行！报告及圆桌讨论嘉宾 Saso Cemerski, Ph.D. AstraZeneca, Executive Director, Head of Immune Engagers Saso joined AZ in May 2021 from CUE Biopharma where they served as VP and Head of Discovery and Translational Immunology developing the company’s early discovery pipeline and enabling the entry of the CUE-101 and CUE-102 into clinical phase I testing. Prior to CUE, Saso was a Principal Scientist at Merck Research Laboratories where they were involved in the development of several IO programs and their transitioning into the clinic, including anti-LAG-3 mAb MK-4280 (as the in vitro biology lead) and two STING agonists MK-1454 and MK-2118 (as the program co-lead). Saso has also held positions in BMS focusing on early discovery autoimmunity programs and in Xencor where they were part of the team that led the advancement of the XmAb5871 program into the clinic. Saso is a trained immunologist with experience across working on programs targeting different immune cell types in different disease indications using both biologics and small molecule approaches. During their academic career at Washington University in St. Louis. Bruce Turner, M.D., Ph.D. Xanadu Bio, Founder, CEO & Chairman Bruce Turner is the managing partner and chief investment officer of Madison Avenue Investors which is a private equity investment vehicle investing in healthcare companies. Currently, Dr. Turner is the CEO of Xanadu Bio and IsoBio, Inc. which are focused on the intranasal delivery of mRNA for immunity, inflammation, oncology, and neurodegeneration, and targeted multi-valent radiotherapeutics, respectively. Dr. Turner was previously a cofounder and chief strategy o icer of Immunome (NASD: IMNM) which is a targeted oncology company focusing on ADC’s and small molecules. Dr. Turner received his M.D., Ph.D. degrees from the University of Pennsylvania School of Medicine and completed his oncology training at Yale University School of Medicine. Wade Blair, Ph.D. IntegerBio, Chief Scientific Officer (CSO) Dr. Blair has 25 years of industry experience at multiple biopharma companies. During his career, Dr. Blair has led numerous drug discovery programs that progressed to clinical trials in infectious disease and oncology. He contributed to the discovery and/or development of six approved drugs, including the HIV capsid inhibitor lenacapavir (Yeztugo), the HIV attachment inhibitor fostemsavir (Rukobia), and the RSV mAb nirsevimab (Beyfortus). In addition, he led the development of a personalized cancer vaccine platform at Gritstone Bio. Dr. Blair currently serves as Chief Scientific Officer of IntegerBio where he oversees immune modulatory programs in virology and oncology. Yi Ding, Ph.D. RA Capital, BD Director Dr. Yi Ding is acting as BD director at RA Capital Swiftbridge, bridging Chinese biotech innovation into global development. She is passionate about identifying innovative healthcare opportunities and supporting their growth; or helping to connect emerging science with international capital and expertise. She holds a Ph.D. from Duke University and a bachelor’s degree from Peking University. Benny Yang, Ph.D. (Moderator) Biocytogen, Chief Scientific Officer (CSO) Dr. Yang graduated from Fudan University with a Master’s degree in Microbiology. He received his Ph.D. degree in Immunology from the University of Connecticut and completed his postdoctoral training at New York University School of Medicine in Dr. Dan Littman’s research group. Then Dr. Yang was recruited to the Medical University of South Carolina (MUSC) as a tenure-track Assistant Professor in the Department of Microbiology and Immunology. In 2016, he joined Biocytogen as the Chief Scientific Officer, where he leads the Institute for Biologics. Dr. Yang has been instrumental in spearheading antibody drug discovery and has overseen the development of dozens of therapeutic antibody-based drugs, successfully advancing multiple projects to IND and clinical stages. 沈月雷博士百奥赛图，董事长兼CEO 沈博士本科毕业于武汉大学病毒学及分子生物学系，先后获得中国食品药品检定研究院免疫学硕士学位、美国马萨诸塞大学医学院免疫学博士学位，并在 HHMI/纽约大学医学院 Dan Littman 实验室从事博士后研究，长期深耕免疫学、基因编辑、模式动物和抗体药物研发等领域，拥有近三十年创新药底层技术与转化研究经验。 2008 年，沈博士在美国创立百奥赛图（股票代码：688796.SH；02315.HK），并带领公司构建了从靶点发现、全人抗体规模化开发、体内药效验证到全球 IND 申报的完整技术体系，打造出“全人抗体库 × 靶点人源化小鼠库”的双引擎平台，使百奥赛图成长为国际化、平台型的新药研发关键伙伴。始终坚持以技术创新驱动全球合作，推动公司向“成为全球新药发源地”的愿景持续迈进。花海清博士映恩生物，高级副总裁、药物发现负责人花海清博士于2003年从清华大学生物系生物技术专业毕业，于2009年从苏黎世大学毕业，获得分子生物学博士学位。毕业后一直从事创新药物的研发和生产。在过去十五年的工作中，花博士主持和参与了多项创新药物的研发，推进10余个产品进入临床研究。刘勇军博士小路生物&拓胜医药，创始人&董事长刘勇军博士于1984年获白求恩医科大学医学学士学位，1989年获英国伯明翰大学医学院免疫学博士学位，随后在该校进行2年的博士后工作。1991年刘博士作为Senior Scientist加入跨国制药公司法国里昂先灵葆雅，2001年加入先灵葆雅旗下美国生物技术公司DNAX研究所担任Principal Staff Scientist。2002年被美国得克萨斯大学安德森癌症中心聘为Vivian L. Smith杰出讲席教授、免疫学系主任和癌症免疫研究中心创始主任。2011年被贝勒研究所聘为首席科学官和贝勒免疫研究所所长。2014年被阿斯利康旗下全球生物制药子公司Medimmune聘为首席科学官和全球研究负责人。2014年至2020年，担任赛诺菲全球研究负责人。2020年至2024年，担任信达生物制药集团总裁。在2025年，刘博士创办了苏州小路生物科技有限公司和合肥拓胜医药科技有限公司，担任董事长一职。刘博士拥有丰富的科研成果，在Nature、Science、Cell等顶尖学术期刊上共发表了超过260篇论文，总引用次数超过10万次，这些研究为免疫学和肿瘤学领域提供了多个关键的药物靶点。刘瑜洁博士百奥赛图，药理药效部总监刘瑜洁博士博士毕业于北京大学药学院，后赴美国伊利诺伊理工大学、西北大学担任高级研究员，专注攻克肿瘤纳米药物跨血脑屏障（BBB）递送系统与肺损伤机制研究等前沿课题。2020年加入百奥赛图后，历任SD、药效资源与产品部经理，现任药理药效部总监，全面负责Biomice CRO业务体系的建设与运营，主导构建了覆盖300+PDX模型的标准化药效资源数据库及智能化数据服务系统。擅长并承接过多项国内外创新药企在肿瘤抗体药药理药效、免疫重建肿瘤药效业务，并且在使用人源化小鼠在临床前抗体药物在跨血脑屏障研究，肿瘤研究、自身免疫疾病领域和PDX应用领域具有丰富的项目经验。 Icy Niu（Moderator）百奥赛图，执行总监 Icy Niu 负责百奥赛图抗体资产的全球合作与授权，推动基于 RenMice 平台的创新抗体实现商业化转化。加入百奥赛图之前，她长期从事抗体发现工作，与多家药企及生物技术公司合作，支持从靶点验证、抗体筛选到早期优化的研发项目，对抗体成药性及转化路径有深入理解。当前，她聚焦推动抗体资产的对外合作与落地转化，通过提供可直接用于开发的抗体分子，帮助合作伙伴更高效地启动并推进药物研发项目，缩短从靶点到候选分子的周期，降低早期研发不确定性。祁昱博士默沙东（MSD），全球业务拓展与授权总监祁昱是默沙东全球业务拓展与授权总监，负责中国地区临床PoC前资产的搜索和评估。她有超过10年的研发和商务拓展经验。她在德国乌尔姆大学获得了分子医学博士学位，研究兴趣主要集中在免疫学、皮肤纤维化和干细胞生物学。徐琳鑫雨博士罗氏（Roche），对外合作部肿瘤领域搜寻与评估负责人徐琳鑫雨博士是一位在临床开发、全球战略及业务发展领域拥有深厚资历的生物医药人才。自2025年7月起，她正式出任对外合作部搜寻与评估负责人。徐博士拥有同济大学医学院医学博士学位。在结束了眼科医生执业生涯后，她于 2016 年投身工业界加入信达生物，负责 PD-1 抑制剂及多款新分子实体 (NME) 在中国及全球的临床开发工作。 2020年加入罗氏后，徐博士深耕早期临床开发领域。2021年至2022年期间，凭借其多元化的能力，她转入对外合作部门，专注于搜寻与评估以及项目交易。此后，她前往瑞士巴塞尔总部任职15个月，以医学总监的角色领导全球临床项目。2023年回国后，她重点负责ADC领域的开发工作，并最终凭借其在临床与商业领域的复合专业经验，领导相关业务开展。方明博士葛兰素史克（GSK），业务拓展高级总监方明博士是葛兰素史克（GSK）业务拓展高级总监，负责在中国市场探寻许可及并购机会。在加入葛兰素史克之前，她担任默克医药（Merck Healthcare KGaA）全球业务拓展与许可事务总监，牵头开展外部创新引进工作，并促进与中国及亚太地区生物制药公司的合作。方明主导了多项与本土创新企业的许可合作项目以及多个研发和临床合作项目。在加入默克之前，方明担任科望医药（Elpiscience Biopharma）业务拓展负责人，领导业务拓展及战略工作。在此职位上，她促成了多笔许可交易及合作项目。她也曾在再鼎医药（Zailab）和诺华（Novartis）任职，专注于外部合作及肿瘤学研发工作。方明在巴黎居里研究所（Curie Institute）完成了博士阶段的学习，拥有法国巴黎皮埃尔和玛丽・居里大学（Université Pierre et Marie Curie）癌症生物学与遗传学专业的博士学位及硕士学位。李哲丰博士礼来制药（Lilly），外部创新合作总监李哲丰博士拥有十余年基因疗法与药物递送的研发经验，他从中山大学毕业后在俄亥俄州立大学接受博士训练，研究方向为小核酸递送。随后加入礼来制药（Eli Lilly and Company）作为礼来基因疗法部门(Lilly Genetic Medicine)的创始团队成员之一专注于核酸药物的递送创新研究。目前主要负责礼来在基因疗法外部创新以及中国创新合作中心的工作。沈蓉博士辉瑞投资有限公司（Pfizer Investment），炎症与免疫领域搜寻与评估及中国本土项目负责人沈蓉女士在医疗产业、投资及咨询领域拥有多年工作经验，现任炎症与免疫领域搜寻与评估及中国本土项目负责人。在加入辉瑞之前，她曾在晨兴创投等知名投资机构任职，从事创新药和新兴技术的投资，并于IQVIA等咨询公司任管理咨询顾问，为跨国药企和本土生物科技公司提供战略支持。沈蓉女士于中国科学技术大学获得化学专业学士学位，后于宾夕法尼亚大学获得生物化学博士学位。江山博士翰森制药集团有限公司，首席技术官前辉瑞生物制药副总裁, 曾经任职于Bayer, BMS,和Seagen的高级管理岗位。从业生物制药领域28年，拥有开发⽣物药的丰富经验。在美国江博曾成功领导多功能CMC 部门获得5款药物全球商业批准，领导并支持更多管线产品从临床前到市场的研发和生产。江博领导翰森制药生物药的开发和生产，管线包括单抗，多抗，融合蛋白，抗体-药物偶联（ADC）药物，负责项目从pre-IND⾄BLA的CMC 开发，供应链管理，以及产品的临床和商业化生产。王卓智博士安博宁生命科技公司，首席科学官安博宁联合创始人和首席科学官，专注于研发新一代TCE用于实体瘤治疗。前药明生物副总裁，领导组建新药研发服务部，管理120+人的新药研发团队, 在公司发展不同阶段负责技术创新、创新药项目立项和管理、临床前开发以及 IND申报。 2024年全球TCE授权记录CN201（CD19 TCE）的药明生物研发负责人，以13亿美元授权默沙东，首付款7亿美元。成功打造具有自主知识产权的WuXiBody® 和SDArBody™等抗体技术平台，以超过10亿美元的合约授权给20+个客户和合作伙伴。 25年生物制药经验，包括领导拜耳抗体工程团队，是抗体屏蔽和酶激活的最早发明人之一，领导多个管线从靶点到临床开发。北京大学肿瘤学博士；加州大学伯克利MBA。赵昊先生君合律师事务所，合伙人赵昊律师是君合律师事务所的合伙人。他具有医药和法学双重背景，并且在加入君合之前就职于恒瑞医药，熟悉药品的早期研发。赵昊律师不仅处理了大量的专利事务和知识产权尽调项目，并且主导了超过200项医药领域的技术交易。赵律师近年主导了百奥赛图跟Ideaya、Gilead、Neurocrine、ABL等交易、德琪和UCB、先声再明与Ipsen和NextCure、嘉和生物跟TRC2004的NewCo交易、宜明昂科跟Instil Bio的许可交易、宜联生物跟BioNtech的平台合作、科望和Astellas的产品+平台合作、嘉越和Erasca、祐森健恒与AZ、加科思和艾力斯、艺妙神州与华东医药等等交易。嘉宾排名不分先后关于百奥赛图百奥赛图（股票代码：688796.SH；02315.HK）是一家创新技术驱动新药研发的国际性生物技术公司，致力于成为全球新药发源地。公司以自主研发的基因编辑技术为核心，构建起“全人抗体分子库 + 靶点人源化小鼠库”的双引擎平台，系统性加速全球药物研发。百奥赛图自主开发了RenMice® 全人抗体平台（涵盖 RenMab®、RenLite®、RenNano®、RenTCR®、RenTCR mimic™），用于治疗性全人单抗、双/多特异性抗体、双抗ADC、纳米抗体以及类TCR抗体等的发现。围绕1000+潜在可成药靶点，公司正推进规模化抗体发现计划——“千鼠万抗™”，已构建超过100万条真实全人抗体序列库，并开放全球合作。截至2025年6月30日，百奥赛图已累计签署约280项药物合作开发 / 授权 / 转让协议。公司子品牌百奥动物已建立数千种基因编辑动物/细胞模型，拥有全球规模领先的靶点人源化小鼠库，并为全球客户提供临床前药理药效研究、基因编辑服务与模型构建等全链条能力支持。百奥赛图总部位于北京，并在中国（江苏海门、上海）、美国（波士顿、旧金山、圣地亚哥）及德国海德堡等地设有分支机构，形成面向全球的研发与运营网络。更多信息请访问官网：https://biocytogen.com.cn/

信使RNA抗体药物偶联物

2026-03-18

·百奥赛图

百奥赛图BioX创新论坛 · 国际版 | 下一个十年的抗体疗法：科学突破，跨国合作与资本逻辑

会议背景在下一个十年的抗体疗法浪潮中，科学突破与跨国协作正成为驱动行业前行的核心引擎。如何从早期分子精准跨越至临床阶段？AI与创新平台如何进一步释放抗体多样性的潜力？跨国BD合作又将如何重塑全球医药资本与产业格局？ 2026年百奥赛图BioX创新论坛将于3月27日在上海盛大开启。本次论坛将汇聚来自全球生物医药企业、创新机构与投资领域的资深专家与行业同仁，共同交流前沿洞见，分享实践经验。论坛将聚焦T Cell Engagers (TCE)、mRNA递送、ADC等前沿赛道，围绕创新技术、产业协同与全球化发展趋势展开深入探讨，共同展望生物医药新纪元下的科学逻辑与商业未来。本次论坛采用报名审核制，席位有限，诚邀感兴趣的行业同仁一起交流！会议信息会议时间 2026年3月27日（周五）8:00-20:00 会议地点上海浦东（详细地址将在确认邮件中通知）会议规模上限100人，报名审核制会议最终解释权归百奥赛图所有会议日程 3月27日 08:00-08:50 会议签到 08:50-09:00 欢迎致辞沈月雷博士-百奥赛图，董事长兼CEO 09:00-09:30 Keynote 1: Development of Novel, CD8-guided, T Cell Engagers for the Treatment of Solid Tumors and Hematological Malignancies Saso Cemerski, Ph.D., AstraZeneca, Executive Director, Head of Immune Engagers 09:30-10:00 Keynote 2: Intranasal Delivery of mRNA for Immunity, Inflammation, and Neurodegeneration Bruce Turner, M.D., Ph.D., Xanadu Bio, Founder, CEO & Chairman 10:00-10:30 Keynote 3: Synthetic Interferons Demonstrate Potent Antiviral and Anti-Tumor Activity with the Potential for an Improved Safety Profile Wade Blair, Ph.D., IntegerBio, CSO 10:30-11:00 Keynote 4: From Capital to Collaboration: Investment and Company Building with China Yi Ding, Ph.D., RA Capital, BD Director 11:00-12:00 Panel 1: The Next Frontier of Innovative Therapeutics: From Early-Stage Molecules to Clinical Trials Benny Yang, Ph.D. (Moderator), Biocytogen, CSO Saso Cemerski, Ph.D., Bruce Turner, M.D., Ph.D., Wade Blair, Ph.D., Yi Ding, Ph.D. 12:00-13:00 午餐 13:00-13:30 Keynote 5: RenSuper Workstation: An AI-Driven Antibody Discovery Platform From Target to Antibody Leads in Clicks 沈月雷博士-百奥赛图，董事长兼CEO 13:30-14:00 Keynote 6: Discovery of Novel ADC DB-1317 and Novel DUP9 Payload 花海清博士-映恩生物，高级副总裁、药物发现负责人 14:00-14:30 Keynote 7: Translating Immunobiology to Medicine 刘勇军博士-小路生物&拓胜医药，创始人&董事长 14:30-15:00 Keynote 8: Accelerating Translation with Integrated Humanized Mouse Models and Pharmacology Platforms 刘瑜洁博士-百奥赛图，药理药效部总监 15:00-15:20 茶歇 15:20-16:20 Panel 1: 谁定义创新药的未来？-- MNC视角 Icy Niu（主持人），百奥赛图， Executive Director, Business & Global Marketing 祁昱博士，默沙东（MSD），全球业务拓展与授权总监方明博士，葛兰素史克（GSK），业务拓展高级总监李哲丰博士，礼来制药（Lilly），外部创新合作总监徐琳鑫雨博士，罗氏（Roche），对外合作部肿瘤领域搜寻与评估负责人 TBD，辉瑞（Pfizer） 16:20-17:20 Panel 2: 谁定义创新药的未来？-- 中国Biotech视角沈月雷博士（主持人）花海清博士，刘勇军博士江山博士，翰森制药集团有限公司，首席技术官赵昊先生，君合律师事务所，合伙人 17:20-20:00 晚宴 & 酒会报名方式 ● 请扫描下方二维码填写报名表单，审核通过后，我们将在会前一周内发送确认邮件，并提供详细会议信息。期待您的加入，共谋行业创新发展，与变革者同行！报告及圆桌讨论嘉宾 Saso Cemerski, Ph.D. AstraZeneca, Executive Director, Head of Immune Engagers Saso joined AZ in May 2021 from CUE Biopharma where they served as VP and Head of Discovery and Translational Immunology developing the company’s early discovery pipeline and enabling the entry of the CUE-101 and CUE-102 into clinical phase I testing. Prior to CUE, Saso was a Principal Scientist at Merck Research Laboratories where they were involved in the development of several IO programs and their transitioning into the clinic, including anti-LAG-3 mAb MK-4280 (as the in vitro biology lead) and two STING agonists MK-1454 and MK-2118 (as the program co-lead). Saso has also held positions in BMS focusing on early discovery autoimmunity programs and in Xencor where they were part of the team that led the advancement of the XmAb5871 program into the clinic. Saso is a trained immunologist with experience across working on programs targeting different immune cell types in different disease indications using both biologics and small molecule approaches. During their academic career at Washington University in St. Louis. Bruce Turner, M.D., Ph.D. Xanadu Bio, Founder, CEO & Chairman Bruce Turner is the managing partner and chief investment officer of Madison Avenue Investors which is a private equity investment vehicle investing in healthcare companies. Currently, Dr. Turner is the CEO of Xanadu Bio and IsoBio, Inc. which are focused on the intranasal delivery of mRNA for immunity, inflammation, oncology, and neurodegeneration, and targeted multi-valent radiotherapeutics, respectively. Dr. Turner was previously a cofounder and chief strategy o icer of Immunome (NASD: IMNM) which is a targeted oncology company focusing on ADC’s and small molecules. Dr. Turner received his M.D., Ph.D. degrees from the University of Pennsylvania School of Medicine and completed his oncology training at Yale University School of Medicine. Wade Blair, Ph.D. IntegerBio, Chief Scientific Officer (CSO) Dr. Blair has 25 years of industry experience at multiple biopharma companies. During his career, Dr. Blair has led numerous drug discovery programs that progressed to clinical trials in infectious disease and oncology. He contributed to the discovery and/or development of six approved drugs, including the HIV capsid inhibitor lenacapavir (Yeztugo), the HIV attachment inhibitor fostemsavir (Rukobia), and the RSV mAb nirsevimab (Beyfortus). In addition, he led the development of a personalized cancer vaccine platform at Gritstone Bio. Dr. Blair currently serves as Chief Scientific Officer of IntegerBio where he oversees immune modulatory programs in virology and oncology. Yi Ding, Ph.D. RA Capital, BD Director Dr. Yi Ding is acting as BD director at RA Capital Swiftbridge, bridging Chinese biotech innovation into global development. She is passionate about identifying innovative healthcare opportunities and supporting their growth; or helping to connect emerging science with international capital and expertise. She holds a Ph.D. from Duke University and a bachelor’s degree from Peking University. Benny Yang, Ph.D. (Moderator) Biocytogen, Chief Scientific Officer (CSO) Dr. Yang graduated from Fudan University with a Master’s degree in Microbiology. He received his Ph.D. degree in Immunology from the University of Connecticut and completed his postdoctoral training at New York University School of Medicine in Dr. Dan Littman’s research group. Then Dr. Yang was recruited to the Medical University of South Carolina (MUSC) as a tenure-track Assistant Professor in the Department of Microbiology and Immunology. In 2016, he joined Biocytogen as the Chief Scientific Officer, where he leads the Institute for Biologics. Dr. Yang has been instrumental in spearheading antibody drug discovery and has overseen the development of dozens of therapeutic antibody-based drugs, successfully advancing multiple projects to IND and clinical stages. 沈月雷博士百奥赛图，董事长兼CEO 沈博士本科毕业于武汉大学病毒学及分子生物学系，先后获得中国食品药品检定研究院免疫学硕士学位、美国马萨诸塞大学医学院免疫学博士学位，并在 HHMI/纽约大学医学院 Dan Littman 实验室从事博士后研究，长期深耕免疫学、基因编辑、模式动物和抗体药物研发等领域，拥有近三十年创新药底层技术与转化研究经验。 2008 年，沈博士在美国创立百奥赛图（股票代码：688796.SH；02315.HK），并带领公司构建了从靶点发现、全人抗体规模化开发、体内药效验证到全球 IND 申报的完整技术体系，打造出“全人抗体库 × 靶点人源化小鼠库”的双引擎平台，使百奥赛图成长为国际化、平台型的新药研发关键伙伴。始终坚持以技术创新驱动全球合作，推动公司向“成为全球新药发源地”的愿景持续迈进。花海清博士映恩生物，高级副总裁、药物发现负责人花海清博士于2003年从清华大学生物系生物技术专业毕业，于2009年从苏黎世大学毕业，获得分子生物学博士学位。毕业后一直从事创新药物的研发和生产。在过去十五年的工作中，花博士主持和参与了多项创新药物的研发，推进10余个产品进入临床研究。刘勇军博士小路生物&拓胜医药，创始人&董事长刘勇军博士于1984年获白求恩医科大学医学学士学位，1989年获英国伯明翰大学医学院免疫学博士学位，随后在该校进行2年的博士后工作。1991年刘博士作为Senior Scientist加入跨国制药公司法国里昂先灵葆雅，2001年加入先灵葆雅旗下美国生物技术公司DNAX研究所担任Principal Staff Scientist。2002年被美国得克萨斯大学安德森癌症中心聘为Vivian L. Smith杰出讲席教授、免疫学系主任和癌症免疫研究中心创始主任。2011年被贝勒研究所聘为首席科学官和贝勒免疫研究所所长。2014年被阿斯利康旗下全球生物制药子公司Medimmune聘为首席科学官和全球研究负责人。2014年至2020年，担任赛诺菲全球研究负责人。2020年至2024年，担任信达生物制药集团总裁。在2025年，刘博士创办了苏州小路生物科技有限公司和合肥拓胜医药科技有限公司，担任董事长一职。刘博士拥有丰富的科研成果，在Nature、Science、Cell等顶尖学术期刊上共发表了超过260篇论文，总引用次数超过10万次，这些研究为免疫学和肿瘤学领域提供了多个关键的药物靶点。刘瑜洁博士百奥赛图，药理药效部总监刘瑜洁博士博士毕业于北京大学药学院，后赴美国伊利诺伊理工大学、西北大学担任高级研究员，专注攻克肿瘤纳米药物跨血脑屏障（BBB）递送系统与肺损伤机制研究等前沿课题。2020年加入百奥赛图后，历任SD、药效资源与产品部经理，现任药理药效部总监，全面负责Biomice CRO业务体系的建设与运营，主导构建了覆盖300+PDX模型的标准化药效资源数据库及智能化数据服务系统。擅长并承接过多项国内外创新药企在肿瘤抗体药药理药效、免疫重建肿瘤药效业务，并且在使用人源化小鼠在临床前抗体药物在跨血脑屏障研究，肿瘤研究、自身免疫疾病领域和PDX应用领域具有丰富的项目经验。 Icy Niu（Moderator）百奥赛图，执行总监 Icy Niu 负责百奥赛图抗体资产的全球合作与授权，推动基于 RenMice 平台的创新抗体实现商业化转化。加入百奥赛图之前，她长期从事抗体发现工作，与多家药企及生物技术公司合作，支持从靶点验证、抗体筛选到早期优化的研发项目，对抗体成药性及转化路径有深入理解。当前，她聚焦推动抗体资产的对外合作与落地转化，通过提供可直接用于开发的抗体分子，帮助合作伙伴更高效地启动并推进药物研发项目，缩短从靶点到候选分子的周期，降低早期研发不确定性。祁昱博士默沙东（MSD），全球业务拓展与授权总监祁昱是默沙东全球业务拓展与授权总监，负责中国地区临床PoC前资产的搜索和评估。她有超过10年的研发和商务拓展经验。她在德国乌尔姆大学获得了分子医学博士学位，研究兴趣主要集中在免疫学、皮肤纤维化和干细胞生物学。徐琳鑫雨博士罗氏（Roche），对外合作部肿瘤领域搜寻与评估负责人徐琳鑫雨（Tracy Xu）博士是一位在临床开发、全球战略及业务发展领域拥有深厚资历的生物医药人才。自2025年7月起，她正式出任对外合作部搜寻与评估负责人。徐博士拥有同济大学医学院医学博士学位。在结束了眼科医生执业生涯后，她于 2016 年投身工业界加入信达生物，负责 PD-1 抑制剂及多款新分子实体 (NME) 在中国及全球的临床开发工作。2020年加入罗氏后，徐博士深耕早期临床开发领域。2021年至2022年期间，凭借其多元化的能力，她转入对外合作部门，专注于搜寻与评估以及项目交易。此后，她前往瑞士巴塞尔总部任职15个月，以医学总监的角色领导全球临床项目。2023年回国后，她重点负责ADC领域的开发工作，并最终凭借其在临床与商业领域的复合专业经验，领导相关业务开展。方明博士葛兰素史克（GSK），业务拓展高级总监方明博士是葛兰素史克（GSK）业务拓展高级总监，负责在中国市场探寻许可及并购机会。在加入葛兰素史克之前，她担任默克医药（Merck Healthcare KGaA）全球业务拓展与许可事务总监，牵头开展外部创新引进工作，并促进与中国及亚太地区生物制药公司的合作。方明主导了多项与本土创新企业的许可合作项目以及多个研发和临床合作项目。在加入默克之前，方明担任科望医药（Elpiscience Biopharma）业务拓展负责人，领导业务拓展及战略工作。在此职位上，她促成了多笔许可交易及合作项目。她也曾在再鼎医药（Zailab）和诺华（Novartis）任职，专注于外部合作及肿瘤学研发工作。方明在巴黎居里研究所（Curie Institute）完成了博士阶段的学习，拥有法国巴黎皮埃尔和玛丽・居里大学（Université Pierre et Marie Curie）癌症生物学与遗传学专业的博士学位及硕士学位。李哲丰博士礼来制药（Lilly），外部创新合作总监李哲丰博士拥有十余年基因疗法与药物递送的研发经验，他从中山大学毕业后在俄亥俄州立大学接受博士训练，研究方向为小核酸递送。随后加入礼来制药（Eli Lilly and Company）作为礼来基因疗法部门(Lilly Genetic Medicine)的创始团队成员之一专注于核酸药物的递送创新研究。目前主要负责礼来在基因疗法外部创新以及中国创新合作中心的工作。江山博士翰森制药集团有限公司，首席技术官前辉瑞生物制药副总裁, 曾经任职于Bayer, BMS,和Seagen的高级管理岗位。从业生物制药领域28年，拥有开发⽣物药的丰富经验。在美国江博曾成功领导多功能CMC 部⻔获得5款药物全球商业批准，领导并支持更多管线产品从临床前到市场的研发和生产。江博领导翰森制药生物药的开发和生产，管线包括单抗，多抗，融合蛋白，抗体-药物偶联（ADC）药物，负责项目从pre-IND⾄BLA的CMC 开发，供应链管理，以及产品的临床和商业化生产。赵昊先生君合律师事务所，合伙人赵昊律师是君合律师事务所的合伙人。他具有医药和法学双重背景，并且在加入君合之前就职于恒瑞医药，熟悉药品的早期研发。赵昊律师不仅处理了大量的专利事务和知识产权尽调项目，并且主导了超过200项医药领域的技术交易。赵律师近年主导了百奥赛图跟Ideaya、Gilead、Neurocrine、ABL等交易、德琪和UCB、先声再明与Ipsen和NextCure、嘉和生物跟TRC2004的NewCo交易、宜明昂科跟Instil Bio的许可交易、宜联生物跟BioNtech的平台合作、科望和Astellas的产品+平台合作、嘉越和Erasca、祐森健恒与AZ、加科思和艾力斯、艺妙神州与华东医药等等交易。嘉宾排名不分先后关于百奥赛图百奥赛图（股票代码：688796.SH；02315.HK）是一家创新技术驱动新药研发的国际性生物技术公司，致力于成为全球新药发源地。公司以自主研发的基因编辑技术为核心，构建起“全人抗体分子库 + 靶点人源化小鼠库”的双引擎平台，系统性加速全球药物研发。百奥赛图自主开发了RenMice® 全人抗体平台（涵盖 RenMab®、RenLite®、RenNano®、RenTCR®、RenTCR mimic™），用于治疗性全人单抗、双/多特异性抗体、双抗ADC、纳米抗体以及类TCR抗体等的发现。围绕1000+潜在可成药靶点，公司正推进规模化抗体发现计划——“千鼠万抗™”，已构建超过100万条真实全人抗体序列库，并开放全球合作。截至2025年6月30日，百奥赛图已累计签署约280项药物合作开发 / 授权 / 转让协议。公司子品牌百奥动物已建立数千种基因编辑动物/细胞模型，拥有全球规模领先的靶点人源化小鼠库，并为全球客户提供临床前药理药效研究、基因编辑服务与模型构建等全链条能力支持。百奥赛图总部位于北京，并在中国（江苏海门、上海）、美国（波士顿、旧金山、圣地亚哥）及德国海德堡等地设有分支机构，形成面向全球的研发与运营网络。更多信息请访问官网：https://biocytogen.com.cn/

信使RNA抗体药物偶联物

2026-03-11

·BioSpace

Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board

New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the appointment of two highly respected and accomplished life sciences research experts to the Company’s Scientific Advisory Board. Together, Dr. Daniel Pascheles and Dr. Nicholas A. Meanwell have contributed more than 75 years of total pharmaceuticals experience, including a combined 50 years at Merck & Co. and Bristol Meyers Squib. Both Advisors will support all commercial strategy, product portfolio development and go-to-market decisions. Biographical experience for these two new advisors is as follows: Daniel Pascheles, Ph.D. Daniel Pascheles is a pharmaceutical executive and strategic consultant with over 25 years of experience building world-class competitive intelligence organizations within global life sciences companies. He is Former CEO and Partner at Molekule Consulting LLC, a firm he joined in 2017 to advise pharmaceutical and biotechnology clients on competitive strategy and market intelligence. Prior to Molekule Consulting, Dr. Pascheles spent 12 years at Merck & Co./MSD as Vice President and Head of Global Competitive Intelligence. Before that, he held senior leadership roles over 14 years at Aventis and its predecessor companies (Hoechst Marion Roussel, Marion Merrell Dow), including Global Head of CI, European Head of Sales and Marketing Administration, European Head of Strategic Planning, and General Manager Switzerland. Dr. Pascheles studied Pharmacy at the Swiss Federal Institute of Technology (ETH) in Zurich and earned his Ph.D. in Pharmaceutical Technology from the same institution. He is Past-President and a current Board member of the Pharmaceutical Business Intelligence & Research Group (PBIRG), a member of the Society of Competitive Intelligence Professionals (SCIP) and the Licensing Executive Society (LES), and a Visiting Professor at Rey Juan Carlos University in Madrid. He has served on the Editorial Advisory Board of Pharmaceutical Executive magazine and is a sought-after speaker and chairman at international conferences on competitive intelligence. Nicholas A. Meanwell, Ph.D. Nicholas A. Meanwell is a distinguished medicinal chemist and drug discovery scientist and a former vice president, who spent four decades at Bristol Myers Squibb (1982–2022), where he led programs across cardiovascular, neurosciences, and virology therapeutic areas. Over the course of his career, Dr. Meanwell and his team advanced 33 clinical candidates, including several that reached patients as approved medicines: the HIV-1 attachment inhibitor fostemsavir (Rukobia ™ ), the HCV NS5A inhibitor daclatasvir (Daklinza ™ ), the HCV NS3 protease inhibitor asunaprevir (Sunvepra ™ ), and the combination product Xymency ™ . Dr. Meanwell has authored or co-authored more than 300 publications, review articles, and book chapters, delivered over 250 invited lectures worldwide, and is named as inventor or co-inventor on 145 issued U.S. patents. He served as Associate Editor of the Journal of Medicinal Chemistry from 2017 to 2023. His contributions to the field have been recognized with numerous prestigious honors, including the 2015 Philip S. Portoghese Medicinal Chemistry Lectureship Award, induction into the ACS Division of Medicinal Chemistry Hall of Fame (2015), ACS "Heroes of Chemistry" Awards (2017, 2023), the 2022 Alfred Burger Award in Medicinal Chemistry, appointment as a Fellow of the American Chemical Society (2022), the 2024 Antonín Holý Memorial Award from the International Society for Antiviral Research, and the 2025 Scientific Achievement in Drug Discovery and Development Award from ASPET. Dr. Meanwell earned his Ph.D. from the University of Sheffield and completed his postdoctoral training with Professor Carl R. Johnson at Wayne State University. Jun Liu, the Chief Executive Officer of Curanex, commented “We are very pleased to welcome Dr. Pascheles and Dr. Meanwell to the Curanex Scientific Advisory Board. Their knowledge and experience will add tremendous depth to our strategic decisions in the coming months as we strive to unlock the potential of our expanding product portfolio.” About Curanex Pharmaceuticals Inc Curanex Pharmaceuticals Inc is a developmental-stage pharmaceutical company headquartered in Jericho, New York, dedicated to discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract from a single plant with proven anti-inflammatory properties that acts via multiple targets and mechanisms. Phyto-N has a long history of human use, having treated thousands of patients with inflammatory diseases over 30 years in China, demonstrating favorable tolerability. The Company has validated Phyto-N's effects in animal models of six inflammatory diseases: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The Company's primary development focus is moderate to severe ulcerative colitis. Phyto-N is currently advancing through FDA-required preclinical studies in preparation for an Investigational New Drug (IND) submission, with Phase I clinical trials targeted to initiate in the fourth quarter of 2026, pending completion of required studies and regulatory clearance. For more information, visit the Company’s website at . Forward-Looking Statements All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements are made as of the date hereof and involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC. For more information, please contact: Curanex Pharmaceuticals Inc Attn: Liqin Xie, Chief Operating Officer info@curanexpharma.com .

临床1期高管变更

100 项与磷坦姆沙韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	磷坦姆沙韦	J05A	DB11796

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
HIV感染	美国	ViiV Healthcare Co.	2020-07-02

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
终末期肾脏病	临床1期	美国	ViiV Healthcare Ltd.	2016-02-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02362503 (BRIGHTE, Pubmed \| Open Forum Infect Dis) 人工标引	临床3期	HIV感染	272	Fostemsavir + optimized background therapy	簾艱餘鏇鹽繭憲憲糧蓋(鏇簾蓋艱構築觸製顧壓) = mean increase, +0.24, CD4+/CD8+ ratio ≥0.45 increased from 9% (25/272) at baseline to 40% (85/213) at week 96. 襯鹹夢膚顧壓淵窪築顧 (築遞餘壓繭築蓋鏇獵蓋 ) 更多	积极	2024-08-30
NCT02362503 (BRIGHTE, Pubmed \| Infect Dis Ther)	临床3期	HIV感染 multidrug-resistant HIV-1	371	Fostemsavir + Optimized Background Therapy	積鑰範積糧繭醖膚齋夢(觸鹽憲膚繭鹹壓願構鏇) = COVID-19-related events occurred in 25 out of 371 participants; all resolved without incident. Four participants discontinued for adverse events, one additional participant experienced a drug-related serious adverse event, and six deaths occurred (median last available CD4+ T-cell count, 3 cells/mm^3) 鬱選夢築積選築獵築顧 (憲選糧顧糧範艱淵鹹窪 )	积极	2023-09-01
				Placebo
NCT02362503 (BRIGHTE, Pubmed \| Antimicrob Agents Chemother)	临床3期	HIV感染	371	Fostemsavir plus optimized background therapy	鏇蓋繭繭繭鏇鹹夢鑰窪(餘餘醖鏇齋鬱鹽醖製獵) = 願簾範鹹範繭製壓鹽襯鑰餘鹽醖蓋艱積蓋選壓 (觸鬱鏇醖夢鏇選網鬱鬱 )	积极	2022-05-03
				Optimized background therapy	鏇蓋繭繭繭鏇鹹夢鑰窪(餘餘醖鏇齋鬱鹽醖製獵) = 蓋鹽窪窪遞製糧網遞觸鑰餘鹽醖蓋艱積蓋選壓 (觸鬱鏇醖夢鏇選網鬱鬱 )
NCT02362503 (BRIGHTE, Pubmed \| Patient)	临床3期	-	371	Fostemsavir (Randomized cohort)	鑰選選築觸憲選齋艱衊(範憲窪顧製積獵鹹夢糧) = 淵鑰築鑰衊淵鹹選窪膚簾繭顧鏇鹽艱鑰製積醖 (壓廠構齋糧顧夢構壓壓 )	-	2021-06-28
				Fostemsavir (Nonrandomized cohort)	鑰選選築觸憲選齋艱衊(範憲窪顧製積獵鹹夢糧) = 壓窪膚糧鑰鹹鬱鬱鑰鏇簾繭顧鏇鹽艱鑰製積醖 (壓廠構齋糧顧夢構壓壓 )
NCT02362503 (BRIGHTE, Pubmed \| Lancet HIV)	临床3期	-	371	Fostemsavir	夢餘壓膚襯糧餘窪網製(鬱廠積窪簾築觸鬱鏇獵) = 鬱鹹憲選衊憲鑰鑰壓願廠選遞壓獵積齋網壓鬱 (築膚顧網遞夢獵築積繭 )	积极	2020-11-01
				Placebo	夢餘壓膚襯糧餘窪網製(鬱廠積窪簾築觸鬱鏇獵) = 積製構淵網膚襯築願襯廠選遞壓獵積齋網壓鬱 (築膚顧網遞夢獵築積繭 )
NCT02362503 (BRIGHTE, Pubmed \| N Engl J Med)	临床3期	HIV感染	371	Fostemsavir	遞鏇襯窪衊鹽醖觸蓋膚(顧鹹鹽蓋廠網鑰築醖鹹) = 鹹製築淵鑰鹹鏇築廠淵簾膚艱範夢築觸遞築衊 (築齋憲齋廠選獵簾鏇夢 )	积极	2020-03-26
				Placebo	遞鏇襯窪衊鹽醖觸蓋膚(顧鹹鹽蓋廠網鑰築醖鹹) = 獵網鏇淵醖願製繭鏇網簾膚艱範夢築觸遞築衊 (築齋憲齋廠選獵簾鏇夢 )
NCT01009814 (CTgov)	临床2期	HIV感染	50	BMS-663068+Ritonavir (BMS-663068 600 mg Q12H + RTV 100 mg Q12H)	積餘願遞襯糧網憲遞繭(構壓顧製鬱衊鑰廠鑰糧) = 鏇糧鹽衊觸廠範獵顧遞鏇齋觸觸艱窪蓋鏇醖鏇 (膚繭鏇蓋膚觸醖壓願觸, 0.07925) 更多	-	2020-01-03
				BMS-663068+Ritonavir (BMS-663068 1200 mg QHS + RTV 100 mg QHS)	積餘願遞襯糧網憲遞繭(構壓顧製鬱衊鑰廠鑰糧) = 壓膚餘鏇鹽觸齋淵艱範鏇齋觸觸艱窪蓋鏇醖鏇 (膚繭鏇蓋膚觸醖壓願觸, 0.10610) 更多
NCT02362503 (BRIGHTE, IAS2019)	N/A	HIV感染	-	Fostemsavir	壓顧鏇齋窪艱選繭蓋鹹(夢築鏇繭獵憲憲鑰壓觸) = 範網鹹積鹹窪憲積廠襯選齋壓憲觸糧範窪糧醖 (鹽醖繭襯簾壓遞憲艱糧 ) 更多	-	2019-01-01
				Placebo	壓顧鏇齋窪艱選繭蓋鹹(夢築鏇繭獵憲憲鑰壓觸) = 鏇範醖築壓製鹹觸蓋鬱選齋壓憲觸糧範窪糧醖 (鹽醖繭襯簾壓遞憲艱糧 ) 更多
NCT02362503 (BRIGHTE study, IAS2019)	N/A	-	-	Fostemsavir-containing regimens	窪範積壓選獵願築積夢(簾鹽獵壓製餘壓觸遞構) = 7% discontinued due to AE 夢鹹鑰鬱蓋膚構築鹽繭 (願蓋簾壓齋鹽鑰餘繭製 ) 更多	-	2019-01-01
NCT01384734 (CTgov)	临床2期	HIV感染	254	FTR+TDF+RAL (FTR 400 mg BID/RAL/TDF)	願繭餘築憲簾襯鹽網鑰 = 糧襯艱壓遞繭襯範獵願繭醖簾憲顧淵遞餘製餘 (壓糧壓獵願夢構窪窪製, 夢壓觸構廠願構鹹齋齋 ~ 襯範鬱顧築構襯遞獵鬱) 更多	-	2018-11-14
				FTR+TDF+RAL (FTR 800 mg BID/RAL/TDF)	願繭餘築憲簾襯鹽網鑰 = 壓淵獵艱膚繭顧築觸構繭醖簾憲顧淵遞餘製餘 (壓糧壓獵願夢構窪窪製, 窪築築鬱糧鏇糧構衊範 ~ 夢廠窪觸鏇廠齋夢壓顧) 更多